Jeffery E. Cobb
GlaxoSmithKline
7 Papers
23 Citations
Jeffery E. Cobb is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Nuclear receptor & Receptor. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
Timothy M. Willson,Jeffery E. Cobb,David J. Cowan,Robert W. Wiethe,Itzela D. Correa,Shimoga R. Prakash,Kelli D. Beck,Linda B. Moore,Steven A. Kliewer,Jürgen M. Lehmann +9 more
719
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα
H. Eric Xu,Thomas B. Stanley,Valerie G. Montana,Millard H. Lambert,Barry G. Shearer,Jeffery E. Cobb,D.D. McKee,Cristin M. Galardi,Kelli D. Plunket,Robert T. Nolte,Derek J. Parks,John T. Moore,Steven A. Kliewer,Timothy M. Willson,Julie B. Stimmel +14 more
TL;DR: Biochemical analyses and structure-based mutagenesis indicate that this mode of co-repressors to nuclear receptors binding is highly conserved across nuclear receptors.
649
A peroxisome proliferator-activated receptor g ligand inhibits adipocyte differentiation
Jennifer L. Oberfield,Jon L. Collins,C Hristopher P. Holmes,Onna M. Goreham,J Oel P. Cooper,Jeffery E. Cobb,J Ames M. Lenhard,Mily A. Hull-Ryde,Hristopher P. Mohr,Steven G. Blanchard,Erek J. Parks,L Inda B. Moore,Jürgen M. Lehmann,Kelli D. Plunket,Ann B. Miller,Ichael V. Milburn,S Teven A. Kliewer,Timothy Mark Willson,Glaxo Wellcome +18 more
- 01 Jan 1999
TL;DR: The peroxisome proliferator-activated receptor (PPAR) subtype plays a central role in the regulation of adipogenesis and is the molecular target for the 2,4-thiazolidinedione class of antidi- abetic drugs.
16
Patent
Nuclear receptor arylating compounds
Steven G. Blanchard,Jeffery E. Cobb,Jon L. Collins,Timothy Mark Willson +3 more
- 13 Mar 2000
TL;DR: In this paper, the present invention discloses novel nuclear receptor ligands of formula (IA) or (IB) which are useful for arylating a cysteine in a nuclear receptor.
7
Patent
Diagnostic methods, therapeutic agents and uses thereof
Luke A. D. Miller,Klaus Peter Adam,Michael V. Milburn,Jeffery E. Cobb,Anne M. Evans,Qibo Zhang +5 more
- 04 Feb 2016
TL;DR: In this article, a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject is presented.